Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cultured chondrocyte implant - Vericel

Drug Profile

Autologous cultured chondrocyte implant - Vericel

Alternative Names: Autologous cultured chondrocytes; Carticel; Carticel II; Cartilage replacement - Genzyme

Latest Information Update: 25 May 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries

Most Recent Events

  • 10 May 2017 Autologous cultured chondrocyte implant - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other countries in South-East Asia
  • 24 Aug 2015 Vericel has patent protection for autologous cultured chondrocyte implant in USA and European Union (Vericel 10-K, August 2015)
  • 24 Nov 2014 Aastrom Biosciences is now called Vericel Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top